ACT Capital Partners L.P. purchased a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 90,400 shares of the biopharmaceutical company’s stock, valued at approximately $5,473,000. Nektar Therapeutics makes up 3.6% of ACT Capital Partners L.P.’s investment portfolio, making the stock its 11th largest position.
Several other institutional investors have also recently made changes to their positions in NKTR. Two Seas Capital LP grew its holdings in Nektar Therapeutics by 8.2% during the 3rd quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company’s stock worth $202,582,000 after acquiring an additional 253,744 shares in the last quarter. Braidwell LP raised its holdings in shares of Nektar Therapeutics by 112.7% in the 2nd quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company’s stock valued at $33,063,000 after purchasing an additional 250,916 shares in the last quarter. Orbimed Advisors LLC bought a new stake in shares of Nektar Therapeutics in the 1st quarter valued at about $19,786,000. ADAR1 Capital Management LLC raised its holdings in shares of Nektar Therapeutics by 123.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 161,252 shares of the biopharmaceutical company’s stock valued at $11,602,000 after purchasing an additional 89,221 shares in the last quarter. Finally, Monashee Investment Management LLC lifted its position in shares of Nektar Therapeutics by 6.2% in the 1st quarter. Monashee Investment Management LLC now owns 100,000 shares of the biopharmaceutical company’s stock worth $7,195,000 after purchasing an additional 5,866 shares during the period. Hedge funds and other institutional investors own 75.88% of the company’s stock.
Insiders Place Their Bets
In other Nektar Therapeutics news, CEO Howard Robin sold 418 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $71.98, for a total value of $30,087.64. Following the completion of the sale, the chief executive officer directly owned 54,627 shares in the company, valued at $3,932,051.46. This trade represents a 0.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is currently owned by company insiders.
Recent Nektar Therapeutics Headlines
Investors following NKTR have been watching these headlines:
- Positive Sentiment: The company reported $952.9 million in cash and marketable securities at quarter-end, providing resources to advance its clinical programs. Nektar Q3 financial results
- Negative Sentiment: Nektar cut its 2026 revenue outlook, a key reason shares were reported down 4.5%. Quarterly revenue of $9.4 million missed the roughly $10.3 million consensus and declined from $11.8 million a year earlier. Zacks Q3 results and outlook
- Negative Sentiment: The net loss widened to $55.7 million from $35.5 million a year ago, while research and development expenses increased. Initial Phase 3 atopic dermatitis data are not expected until mid-2028, leaving a lengthy wait for a major clinical catalyst. Q3 loss and pipeline update
Nektar Therapeutics Trading Up 0.1%
Shares of NASDAQ:NKTR traded up $0.02 during trading on Friday, reaching $37.27. The stock had a trading volume of 695,154 shares, compared to its average volume of 647,392. Nektar Therapeutics has a one year low of $33.40 and a one year high of $109.00. The company has a market capitalization of $1.27 billion, a P/E ratio of -5.77 and a beta of 1.44. The firm’s 50-day simple moving average is $48.47 and its 200 day simple moving average is $64.54.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.07) by $0.44. The firm had revenue of $9.39 million for the quarter, compared to the consensus estimate of $10.27 million. Nektar Therapeutics had a negative net margin of 339.67% and a negative return on equity of 33.89%. Equities research analysts forecast that Nektar Therapeutics will post -8.08 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on NKTR. UBS Group started coverage on shares of Nektar Therapeutics in a research note on Monday, October 12th. They set a “neutral” rating and a $53.00 price objective on the stock. Wall Street Zen downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. BTIG Research restated a “buy” rating and set a $178.00 target price on shares of Nektar Therapeutics in a report on Friday, October 9th. Canaccord Genuity Group initiated coverage on Nektar Therapeutics in a report on Wednesday, July 22nd. They set a “buy” rating and a $153.00 target price for the company. Finally, Raymond James Financial initiated coverage on Nektar Therapeutics in a research report on Friday, October 9th. They set a “market perform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $130.67.
Read Our Latest Stock Report on NKTR
Nektar Therapeutics Profile
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.
Further Reading
- Five stocks we like better than Nektar Therapeutics
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR – Free Report).
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
